First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
Conditions: Solid Tumor, Adult; FGFR2 Amplification; FGFR2 Gene Mutation; FGFR2 Gene Rearrangement; FGFR2 Gene Translocation; FGFR2 Gene Activation; Intrahepatic Cholangiocarcinoma; Cholangiocarcinoma; Endometrial Cancer; Gastric Cancer; Breast Cancer Intervention: Drug: RLY-4008 Sponsor: Relay Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bile Duct Cancer | Cancer | Cancer & Oncology | Cholangiocarcinoma | Gastroenterology | Research | Study | Translocation